1. Long-Term Outcomes of Childhood Acute Lymphocytic Leukemia Treated with Adapted Berlin–Frankfurt–Münster (BFM) Protocols: A Multicentric Analysis from a Developing Country.
- Author
-
Horn, Patricia Regina Cavalcanti Barbosa, Ribeiro-Carvalho, Marilza de Moura, Azevedo, Alice Maria Boulhosa de, Sousa, Adriana Martins de, Faria, Simone, Wiggers, Cristina, Rouxinol, Soraia, Schramm, Marcia Trindade, Sanches, Bárbara Sarni, Duarte, Nathalia Lopez, Seixas, Teresa de Souza Fernandez, Gomes, Bernadete Evangelho, Oliveira, Elen de, Arcuri, Leonardo Javier, Costa, Elaine Sobral da, Land, Marcelo Gerardin Poirot, and Souza, Maria Helena Faria Ornellas de
- Subjects
- *
LYMPHOBLASTIC leukemia treatment , *MEDICAL protocols , *FLOW cytometry , *TUMORS in children , *HUMAN services programs , *METHOTREXATE , *ANTINEOPLASTIC agents , *POLYMERASE chain reaction , *TREATMENT effectiveness , *RETROSPECTIVE studies , *CANCER chemotherapy , *ODDS ratio , *RESEARCH , *ASPARAGINASE , *PATIENT monitoring , *GENERIC drug substitution , *SURVIVAL analysis (Biometry) , *COMPARATIVE studies , *PROGRESSION-free survival , *CHILDREN ,DEVELOPING countries - Abstract
Simple Summary: Berlin–Frankfurt–Münster (BFM) protocols are widely used outside clinical trials to treat pediatric acute lymphoblastic leukemia patients. However, local specificities might demand treatment adaptations, like the reduction of high-dose methotrexate due to lack of pharmacokinetic monitoring, the substitution of conventional asparaginase for peg-asparaginase because of the unavailability of the latter, or flow-cytometry-based measurable residual disease instead of a PCR-based one. Here, we report the results of a 22-year period of children treated with BFM protocols in a developing country. The results were somewhat comparable to the BFM reports, and we conclude that BFM protocol adaptations can be safely implemented in developing countries, accounting for local specificities. Introduction: The objective of the current study was to determine the survival probabilities of children and adolescents with acute lymphocytic leukemia treated with adapted Berlin–Frankfurt–Münster (BFM) protocols and compare our results with the original BFM reports. Methods: This retrospective study included 695 patients up to 19 years old treated with adapted BFM protocols between 1997 and 2018 in four hospitals in Rio de Janeiro. The 1997–2007 and 2008–2018 cohorts were analyzed separately. Results: More than half of the patients were stratified into the high-risk BFM classification. Overall and event-free survivals were, in the 1997–2007 period, respectively, 88% and 80% (BFM standard risk group—SRG), 75% and 67% (intermediate risk group—IRG), and 48% and 33% (high-risk group—HRG). The corresponding numbers for the 2008–2018 period were 93% and 84% (SRG), 75% and 63% (IRG), and 64% and 57% (HRG). In the second period, both the OS (HR = 0.71, p = 0.011) and EFS (HR = 0.62, p < 0.001) were higher. Except for the intermediate-risk group, the latter results are comparable to the BFM. Conclusion: The BFM protocol adaptations can be safely implemented in developing countries, accounting for local specificities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF